U.S. Markets closed

Aethlon Medical, Inc. (AEMD)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.6700+0.1200 (+4.71%)
At close: 4:00PM EST

2.6700 0.00 (0.00%)
After hours: 7:41PM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.5500
Open2.6000
Bid2.6600 x 1100
Ask2.7300 x 1300
Day's Range2.5696 - 2.7700
52 Week Range1.1800 - 4.3400
Volume568,926
Avg. Volume1,983,158
Market Cap32.276M
Beta (5Y Monthly)0.68
PE Ratio (TTM)N/A
EPS (TTM)-0.7060
Earnings DateFeb 08, 2021 - Feb 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
  • Aethlon Medical Expands Leadership Team with Appointment of Chief Business Officer and Chief Medical Officer
    PR Newswire

    Aethlon Medical Expands Leadership Team with Appointment of Chief Business Officer and Chief Medical Officer

    Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, today announced the expansion of its executive team with two key appointments: Guy Cipriani as Senior Vice President and Chief Business Officer, and Steven LaRosa, M.D., as Chief Medical Officer. In his new role, Mr. Cipriani will oversee business development and partnerships, while also contributing to fundraising and corporate development. Dr. LaRosa will be responsible for the clinical development of Aethlon's Hemopurifier®, including leading clinical operations and regulatory strategy.

  • Aethlon Medical to Present at the H.C. Wainwright BioConnect 2021 Conference
    PR Newswire

    Aethlon Medical to Present at the H.C. Wainwright BioConnect 2021 Conference

    Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, today announced that the company will participate in the virtual H.C. Wainwright BioConnect 2021 Conference to be held Jan. 11-14, 2021.

  • Aethlon Medical Announces First Patient Treated in First-in-Human Clinical Trial of HEMOPURIFIER® in Head and Neck Cancer
    PR Newswire

    Aethlon Medical Announces First Patient Treated in First-in-Human Clinical Trial of HEMOPURIFIER® in Head and Neck Cancer

    Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, announced today that the first patient has been treated in the Company's first-in-human Early Feasibility Study (EFS) evaluating the HEMOPURIFIER® in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. The study is enrolling patients at UPMC Hillman Cancer Center in Pittsburgh, PA. (Hemopurifier Plus Pembrolizumab in Head and Neck Cancer - Full Text View - ClinicalTrials.gov).